Global Veterinary Antimicrobial Susceptibility Testing Market Size study, by Animal Type (Production, Companion), Product (Accessories & Consumables, Automated AST Instruments), End-use and Regional Forecasts 2022–2032

Global Veterinary Antimicrobial Susceptibility Testing Market is valued at approximately USD 1.02 billion in 2023 and is anticipated to grow with a healthy CAGR of more than 5.80% over the forecast period 2024–2032. In an era where antimicrobial resistance (AMR) is posing a formidable threat to both human and animal health, veterinary antimicrobial susceptibility testing (AST) has emerged as a critical component of responsible animal healthcare practices. This testing method provides targeted insights into the effectiveness of antimicrobial agents against specific bacterial strains in animals, enabling veterinarians to prescribe precision therapies while curbing indiscriminate antibiotic use. As the focus on One Health intensifies—linking human, animal, and environmental well-being—AST has become indispensable in maintaining biosecurity, safeguarding livestock productivity, and preserving the efficacy of antimicrobial drugs.

The robust trajectory of this market is being fueled by the mounting regulatory emphasis on antibiotic stewardship and surveillance, particularly in high-output livestock economies. With production animals (such as cattle, poultry, and swine) forming the backbone of global food supply chains, early detection and tailored treatment of bacterial infections through AST are proving to be cost-effective and productivity-enhancing. Additionally, growing pet ownership and rising incidences of zoonotic infections in companion animals are accelerating the demand for antimicrobial sensitivity tests in veterinary clinics. Innovations in automated AST instruments and rapid testing consumables are improving turnaround times and diagnostic accuracy, offering veterinarians a powerful tool for clinical decision-making.

Nonetheless, the market’s expansion is not without hurdles. High instrument costs, especially for automated systems, deter adoption in smaller clinics and developing regions. Additionally, fragmented infrastructure and a lack of standardized testing protocols across veterinary institutions often result in diagnostic variability. Resistance from end-users to shift from empirical treatment to evidence-based antibiotic administration also impedes the full-scale penetration of AST solutions. However, concerted efforts by global health agencies, academic institutions, and animal health companies to raise awareness and provide subsidized access to AST equipment are gradually unlocking underpenetrated territories.

Technology is steadily transforming this diagnostic landscape. Next-generation sequencing (NGS), microfluidic-based platforms, and AI-integrated diagnostic tools are beginning to redefine the boundaries of AST by offering high-throughput, point-of-care solutions with predictive analytics. Veterinary clinics and laboratories are also leveraging cloud-connected diagnostic platforms to streamline sample tracking, facilitate remote consultations, and integrate with veterinary practice management systems. These digital advancements are expected to further propel the shift from manual to automated, standardized testing ecosystems in both production and companion animal sectors.

Regionally, North America leads the global veterinary antimicrobial susceptibility testing market, driven by stringent antimicrobial use guidelines, widespread pet insurance coverage, and a strong presence of diagnostic innovators. Europe trails closely behind, buoyed by robust surveillance frameworks and harmonized animal health regulations. Meanwhile, the Asia Pacific region is projected to witness the fastest growth, fueled by rising meat consumption, heightened government vigilance against AMR, and the growing number of public-private partnerships in veterinary infrastructure development. Latin America and the Middle East & Africa are evolving into promising markets due to increasing veterinary education programs and expanding agricultural export policies requiring certified antimicrobial controls.

Major market player included in this report are:
• Zoetis Inc.
• IDEXX Laboratories, Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• Vetoquinol S.A.
• Merck Animal Health
• Neogen Corporation
• Heska Corporation
• Biomérieux SA
• Creative Diagnostics
• Randox Laboratories Ltd.
• Roche Diagnostics
• Bioguard Corporation
• Promega Corporation

The detailed segments and sub-segment of the market are explained below:

By Animal Type
• Production
• Companion

By Product
• Accessories & Consumables
• Automated AST Instruments

By End-use
• Veterinary Hospitals & Clinics
• Research Institutes
• Reference Laboratories

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical Year – 2022
• Base Year – 2023
• Forecast Period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.